MX2022002152A - Agonistas biciclicos del estimulador de genes de interferon sting. - Google Patents

Agonistas biciclicos del estimulador de genes de interferon sting.

Info

Publication number
MX2022002152A
MX2022002152A MX2022002152A MX2022002152A MX2022002152A MX 2022002152 A MX2022002152 A MX 2022002152A MX 2022002152 A MX2022002152 A MX 2022002152A MX 2022002152 A MX2022002152 A MX 2022002152A MX 2022002152 A MX2022002152 A MX 2022002152A
Authority
MX
Mexico
Prior art keywords
formula
sting
stimulator
compounds
bicyclic
Prior art date
Application number
MX2022002152A
Other languages
English (en)
Inventor
Hank Michael James Petrassi
Kristen Johnson
Peter G Schultz
Arnab K Chatterjee
Luke L Lairson
Chenguang Yu
Jie Wang
Alan Chu
Emily Chin
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Publication of MX2022002152A publication Critical patent/MX2022002152A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente divulgación proporciona compuestos que tienen una bioactividad agonística estimuladora de genes de interferón (STING, por sus siglas en inglés) que puede utilizarse en el tratamiento de tumores en pacientes que sufren de esto. Los compuestos son un compuesto de la fórmula (I) o la fórmula (II): (ver formula I) (ver formula II) en donde los sustitutos son conforme a lo definido en la presente. El anillo A es un sistema de anillos heteroarilo bicíclico completamente aromático o parcialmente reducido que comprende 3, 4 o 5 N átomos, sustituidos por 0, 1, 2, 3 o 4 sustitutos conforme a lo definido en la presente. Los compuestos para la práctica de un método de la presente divulgación pueden administrarse oralmente para una exposición sistémica, así como administrarse de manera intratumoral. La terapia antitumoral mediante un compuesto de la fórmula (I) puede comprender además la administración de una dosis efectiva de un fármaco dirigido a los puntos de control inmunológicos.
MX2022002152A 2019-08-21 2020-08-21 Agonistas biciclicos del estimulador de genes de interferon sting. MX2022002152A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962889679P 2019-08-21 2019-08-21
PCT/US2020/070444 WO2021035258A1 (en) 2019-08-21 2020-08-21 Bicyclic agonists of stimulator of interferon genes sting

Publications (1)

Publication Number Publication Date
MX2022002152A true MX2022002152A (es) 2022-05-18

Family

ID=72381173

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022002152A MX2022002152A (es) 2019-08-21 2020-08-21 Agonistas biciclicos del estimulador de genes de interferon sting.

Country Status (10)

Country Link
US (1) US20220332720A1 (es)
EP (1) EP4017593A1 (es)
JP (1) JP7414965B2 (es)
KR (1) KR20220066067A (es)
CN (1) CN115003383A (es)
AU (1) AU2020333990B2 (es)
CA (1) CA3151850A1 (es)
IL (1) IL290771A (es)
MX (1) MX2022002152A (es)
WO (1) WO2021035258A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220167275A (ko) 2020-04-10 2022-12-20 오노 야꾸힝 고교 가부시키가이샤 암 치료 방법

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657893A (en) * 1984-05-09 1987-04-14 Syntex (U.S.A.) Inc. 4H-3,1-benzoxazin-4-ones and related compounds and use as enzyme inhibitors
US5262537A (en) * 1993-03-19 1993-11-16 Anaquest, Inc. Derivatives of 4,5,6,7-tetrahydroimidazo-[4,5-c]pyridinyl-6-carboxylic acid
GB9424379D0 (en) * 1994-12-02 1995-01-18 Agrevo Uk Ltd Fungicides
JPWO2003002558A1 (ja) * 2001-06-13 2004-10-14 旭化成ファーマ株式会社 ウイルス感染治療剤
BR0307588A (pt) * 2002-02-22 2005-02-01 Teijin Ltd Composto, inibidor de gsk-3, composição farmacêutica, e, agente terapêutico ou preventivo para uma doença
US20090239982A1 (en) 2007-03-30 2009-09-24 Fujifilm Corporation Ultraviolet Absorbent and Heterocyclic Compound
RU2341527C1 (ru) * 2007-07-17 2008-12-20 Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" Аннелированные азагетероциклы, включающие пиримидиновый фрагмент, способ их получения и ингибиторы pi3k киназ
TR201810523T4 (tr) * 2010-12-08 2018-08-27 Health Glukoserebrosidaz aktivatörleri olarak ornatımlı pirazolopirimidinler.
JP2016501883A (ja) * 2012-12-07 2016-01-21 シガ テクノロジーズ，インコーポレーテッド デングウイルス感染症の治療及び予防のためのチエノピリジン誘導体
US20170146519A1 (en) * 2015-11-20 2017-05-25 Oregon Health & Science University Sting agonists and methods of selecting sting agonists
UA125223C2 (uk) 2016-10-04 2022-02-02 Мерк Шарп І Доум Корп. СПОЛУКИ БЕНЗО[b]ТІОФЕНУ ЯК АГОНІСТИ STING
AR113224A1 (es) 2017-04-28 2020-02-19 Novartis Ag Conjugados de anticuerpo que comprenden un agonista de sting
GB2563642A (en) * 2017-06-22 2018-12-26 Curadev Pharma Ltd Small molecule modulators of human STING
SG11202002218VA (en) 2017-09-15 2020-04-29 Aduro Biotech Inc Pyrazolopyrimidinone compounds and uses thereof
US11701364B2 (en) * 2018-02-21 2023-07-18 The Scripps Research Institute Agonists of stimulator of interferon genes sting

Also Published As

Publication number Publication date
CA3151850A1 (en) 2021-02-25
IL290771A (en) 2022-04-01
AU2020333990A1 (en) 2022-04-07
EP4017593A1 (en) 2022-06-29
JP7414965B2 (ja) 2024-01-16
CN115003383A (zh) 2022-09-02
JP2022545006A (ja) 2022-10-24
WO2021035258A1 (en) 2021-02-25
KR20220066067A (ko) 2022-05-23
AU2020333990B2 (en) 2024-05-23
US20220332720A1 (en) 2022-10-20

Similar Documents

Publication Publication Date Title
MX2020008771A (es) Agonistas del estimulador de genes interferon.
PH12020551717A1 (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
HK1104968A1 (en) Use of immunomodulatory compounds in the manufacture of a medicament for the treatment and management of cancers and other diseases, and compositions thereof
MXPA05012155A (es) Metodos y composiciones que utilizan compuestos inmunomoduladores para el tratamiento y manejo de canceres y otras enfermedades.
TW200500355A (en) Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
SG11201806438UA (en) Fused Pyrazole Derivatives, Preparation Method Thereof, And Use Thereof In Treatment Of Cancers, Inflammation And Immune Diseases
MX339142B (es) Combinaciones y metodos de administracion de agentes terapeuticos y terapia de combinacion.
MX2022000430A (es) Administracion de agonista de sting e inhibidores de puntos de control.
MX2020010942A (es) Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales.
MX2022002144A (es) Agonistas monocíclicos de estimulador de genes interferón sting.
MX2022015629A (es) Uso de vibegron para tratar vejiga sobreactiva.
JOP20200244A1 (ar) مشتقات بلاديينوليد كعوامل تستهدف جسيمات الوصل لعلاج السرطان
MX2022002152A (es) Agonistas biciclicos del estimulador de genes de interferon sting.
RU2015114967A (ru) Производные ингенола, применяемые для лечения рака
PH12019500858A1 (en) Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
WO2022046452A3 (en) Nanoparticulate system for delivery of pain relief agents
PH12020551715A1 (en) Methods of treating cancer
MX2023005295A (es) Tratamiento contra el cancer resistente a platino.
MX2023010394A (es) Metodos para tratar el cancer usando una combinacion de regimenes de dosificacion de serd.
MX2023007150A (es) Compuestos de pirazol que contienen boro, composiciones que los comprenden, métodos y usos de los mismos.
JOP20170044B1 (ar) تركيبة صيدلانية تشتمل على hgh ناتج عن عودة الارتباط الجيني لعلاج نقص هرمون النمو
WO2022174064A3 (en) Therapeutic composition and method combining multiplex immunotherapy with cancer vaccine for the treatment of cancer
RU2013149175A (ru) Лекарственное средство, содержащее лектины омелы, для лечения злокачественной меланомы
MX2014001221A (es) Metodo para tratar el cancer mediante el uso combinado de farmacos.
PH12021550471A1 (en) Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety